Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation.

Abstract

A historical review of the development of cytomegalovirus hyperimmune globulin (CMV-IG, CytoGam) shows its increasing use in solid organ transplant (SOT) recipients, either alone or in combination with ganciclovir. A review of clinical trials of CytoGam in renal transplant recipients shows reductions in CMV-associated syndromes and fungal and parasitic superinfections, and increases in graft survival, while CytoGam prophylaxis trials in orthotopic liver transplant (OLT) recipients have produced reductions in severe CMV-associated disease and invasive fungal disease. A combination of CytoGam plus ganciclovir in OLT recipients has resulted in reductions in CMV hepatitis and infection, and CMV disease and viremia, plus a trend in improved 1- and 2-year survival rates.

• Authors: D R Snydman
• Journal: Transplant infectious disease : an official journal of the Transplantation Society (Transpl Infect Dis) Vol. 3 Suppl 2 Pg. 6-13 ( 2001) ISSN: 1398-2273 [Print] Denmark
• PMID: 11926753 (Publication Type: Journal Article, Review)

Chemical References

• Antiviral Agents
• Immunoglobulins
• Immunoglobulins, Intravenous
• cytomegalovirus-specific hyperimmune globulin

Topics

• Antiviral Agents (therapeutic use)
• Cytomegalovirus (isolation & purification)
• Cytomegalovirus Infections (drug therapy, prevention & control)
• Graft Survival
• Humans
• Immunoglobulins (therapeutic use)
• Immunoglobulins, Intravenous
• Kidney Transplantation (adverse effects)
• Liver Transplantation (adverse effects)